Nithya Baburajendran
Overview
Explore the profile of Nithya Baburajendran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loh Y, Anantharajan J, Huang Q, Xu W, Fulwood J, Ng H, et al.
Protein Sci
. 2024 Feb;
33(3):e4904.
PMID: 38358126
UBE2T is an attractive target for drug development due to its linkage with several types of cancers. However, the druggability of ubiquitin-conjugating E2 (UBE2T) is low because of the lack...
2.
Anantharajan J, Tan Q, Fulwood J, Sifang W, Huang Q, Ng H, et al.
Biochem Biophys Res Commun
. 2023 Nov;
689:149238.
PMID: 37979329
UBE2T is an E2 ubiquitin ligase critical for ubiquitination of substrate and plays important roles in many diseases. Despite the important function, UBE2T is considered as an undruggable target due...
3.
Anantharajan J, Baburajendran N, Lin G, Loh Y, Xu W, Ahmad N, et al.
Protein Sci
. 2021 Nov;
31(2):422-431.
PMID: 34761455
Human eyes absent (EYA) proteins possess Tyr phosphatase activity, which is critical for numerous cancer and metastasis promoting activities, making it an attractive target for cancer therapy. In this work,...
4.
Ng P, Foo K, Sim S, Wang G, Huang C, Tan L, et al.
Bioorg Med Chem
. 2021 Oct;
49:116437.
PMID: 34600239
AXL is a member of the TAM (TYRO3, AXL, MER) subfamily of receptor tyrosine kinases. It is upregulated in a variety of cancers and its overexpression is associated with poor...
5.
Quach D, Tang G, Anantharajan J, Baburajendran N, Poulsen A, Wee J, et al.
Angew Chem Int Ed Engl
. 2021 May;
60(31):17131-17137.
PMID: 34008286
Targeted covalent inhibitors have re-emerged as validated drugs to overcome acquired resistance in cancer treatment. Herein, by using a carbonyl boronic acid (CBA) warhead, we report the structure-based design of...
6.
Escande-Beillard N, Loh A, Saleem S, Kanata K, Hashimoto Y, Altunoglu U, et al.
Neuron
. 2020 Apr;
107(1):82-94.e6.
PMID: 32330411
Patients lacking PYCR2, a mitochondrial enzyme that synthesizes proline, display postnatal degenerative microcephaly with hypomyelination. Here we report the crystal structure of the PYCR2 apo-enzyme and show that a novel...
7.
Kwiatkowski J, Liu B, Pang S, Ahmad N, Wang G, Poulsen A, et al.
J Med Chem
. 2020 Jan;
63(2):621-637.
PMID: 31910010
Dysregulation of translation initiation factor 4E (eIF4E) activity occurs in various cancers. Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) play a fundamental role in activation...
8.
Huang C, Liew S, Lin G, Poulsen A, Ang M, Chia B, et al.
ACS Med Chem Lett
. 2019 Aug;
10(8):1240.
PMID: 31413812
[This corrects the article DOI: 10.1021/acsmedchemlett.9b00170.].
9.
Anantharajan J, Zhou H, Zhang L, Hotz T, Vincent M, Blevins M, et al.
Mol Cancer Ther
. 2019 Jul;
18(9):1484-1496.
PMID: 31285279
EYA proteins (EYA1-4) are critical developmental transcriptional cofactors that contain an EYA domain (ED) harboring Tyr phosphatase activity. EYA proteins are largely downregulated after embryogenesis but are reexpressed in cancers,...
10.
Huang C, Liew S, Lin G, Poulsen A, Ang M, Chia B, et al.
ACS Med Chem Lett
. 2019 Jun;
10(6):978-984.
PMID: 31223458
SMYD3 is a histone methyltransferase that regulates gene transcription, and its overexpression is associated with multiple human cancers. A novel class of tetrahydroacridine compounds which inhibit SMYD3 through a covalent...